Bufexamac can cause severe [[contact dermatitis]] which is often hard to distinguish from the initial condition.<ref>{{cite journal|url=http://www.akdae.de/Arzneimittelsicherheit/Bekanntgaben/Archiv/2000/20001124.html|title=Bufexamac: Ein Ekzemtherapeutikum, das selbst häufig allergische Kontaktekzeme hervorruft|language=German|journal=Deutsches Ärzteblatt|issue=47|year=2000}}</ref> As a consequence, the [[European Medicines Agency]] recommended to withdraw the marketing approval in April 2010.<ref>{{cite news|publisher=European Medicines Agency|title=European Medicines Agency recommends revocation of marketing authorisations for bufexamac |url=http://www.ema.europa.eu/pdfs/human/referral/bufexamac/24639510en.pdf|date=2010-04-22}}</ref>

 

